PROTACs as a New Tactic to Treat Cancer

Cancer's high mortality, medication resistance, and recurrence rates make it a significant worldwide health concern. Despite improvements in immunotherapy and targeted therapy, its effectiveness is hampered by issues including acquired resistance. Among the innovative treatment approaches being investigated to address these issues, proteolysis-targeting chimeras (PROTACs) have shown promise. By selectively degrading target proteins, PROTACs provide a catalytic, long-lasting and low side effect mechanism of action in contrast to conventional small molecule inhibitors that impede protein function. In this review, the design, mechanisms, and uses of PROTACs in cancer treatment are examined. The development of PROTAC based cancer treatments is given a wider vision and additional alternatives thanks to this review, which also examines current issues like pharmacokinetics, cell membrane permeability, E3 ligase selection, and off-target effects et al. The information in this evaluation is intended to be used as a guide for future clinical translation and optimization of medications based on PROTACs.